论文部分内容阅读
目的:探讨地西他滨联合CAG方案在老年急性髓系白血病(AML)中的临床疗效。方法:将60例老年AML患者按照随机数字法分为对照组和观察组,每组30例。对照组采用CAG方案治疗,观察组联合地西他滨治疗,比较2组临床疗效、生存率及毒副反应发生率情况。结果:观察组和对照组治疗后临床缓解率分别为73.33%,50.00%,2组比较差异有统计学意义(P<0.05)。观察组和对照组治疗后毒副反应发生率分别为30.00%,26.67%,2组比较差异无统计学意义(P>0.05)。2组治疗后5年生存率比较差异无统计学意义(P>0.05)。观察组治疗后1年、3年生存率显著高于对照组(P<0.05)。观察组治疗后无病生存期和无事件生存期长于对照组(P<0.05)。结论:老年AML患者在CAG方案治疗基础上联合地西他滨治疗效果理想,能提高生存率,毒副反应发生率较低,值得推广应用。
Objective: To investigate the clinical efficacy of decitabine combined with CAG in elderly patients with acute myeloid leukemia (AML). Methods: Sixty elderly AML patients were divided into control group and observation group according to random number method, 30 cases in each group. The control group was treated with CAG regimen, and the observation group was treated with decitabine. The clinical efficacy, survival rate and incidence of adverse reactions in the two groups were compared. Results: The clinical remission rates of the observation group and the control group after treatment were 73.33% and 50.00%, respectively. There was significant difference between the two groups (P <0.05). The incidence of adverse reactions in the observation group and the control group after treatment was 30.00% and 26.67% respectively. There was no significant difference between the two groups (P> 0.05). There was no significant difference in 5-year survival rate between the two groups (P> 0.05). One year after treatment, the 3-year survival rate in the observation group was significantly higher than that in the control group (P <0.05). The disease-free survival and event-free survival of the observation group were longer than those of the control group (P <0.05). Conclusion: Elderly patients with AML combined with decitabine on the basis of CAG regimen are effective in improving the survival rate and the incidence of toxic and side effects, which is worthy to be popularized and applied.